Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

CARsgen Therapeutics (2171.HK)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (HK$) Price Target (HK$) Rating
2022-02-2819.0653.00Buy
2022-04-1214.4638.00Buy
2022-08-2417.4434.50Buy
2022-12-1316.2618.00Neutral
2023-03-2314.4416.30Neutral
2023-08-149.99-No Rating
2023-08-309.4911.50Neutral
2024-03-116.19-No Rating
2024-04-255.335.80Neutral
2024-10-233.99-No Rating
2024-10-305.005.80Neutral
2024-12-149.6811.50Buy
2025-03-1713.74-No Rating
2025-03-1913.0011.50Buy
2025-04-0811.16-No Rating

Disclosures

  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.